VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Patients with a histologically or cytologically    │ Patients with a histologically or cytologically    │     100 │
│ proven diagnosis of NSCLC                          │ proven diagnosis of NSCLC                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unresectable (locally advanced) stage IIIa or IIIb │ Unresectable (locally advanced) stage IIIa or IIIb │     100 │
│ disease                                            │ disease                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Initial radiotherapy field of treatment to         │ Initial radiotherapy field of treatment to         │     100 │
│ encompass greater than or equal to 30% of the      │ encompass greater than or equal to 30% of the      │         │
│ esophagus                                          │ esophagus                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Life expectancy greater than or equal to 6 months  │ Life expectancy greater than or equal to 6 months  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Estimated weight loss less than or equal to 10% in │ Estimated weight loss less than or equal to 10% in │     100 │
│ the 3 months before study randomization            │ the 3 months before study randomization            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Measurable disease                                 │ Measurable disease                                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ 18 years of age or older                           │ 18 years of age or older                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Eastern Cooperative Oncology Group (ECOG)          │ Eastern Cooperative Oncology Group (ECOG)          │     100 │
│ performance status of 0 - 2                        │ performance status of 0 - 2                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hemoglobin (hgb) greater than or equal to 10 g/dL  │ Hemoglobin (hgb) greater than or equal to 10 g/dL  │     100 │
│ without transfusional support or growth factor use │ without transfusional support or growth factor use │         │
│ in the 4 weeks before study randomization          │ in the 4 weeks before study randomization          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Absolute neutrophil count (ANC) greater than or    │ Absolute neutrophil count (ANC) greater than or    │     100 │
│ equal to 1.5 x 10\^9/L without growth factor use   │ equal to 1.5 x 10^9/L without growth factor use in │         │
│ in the 2 weeks before study randomization          │ the 2 weeks before study randomization             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum bilirubin less than or equal to 1.5 x        │ Serum bilirubin less than or equal to 1.5 x        │     100 │
│ institutional upper limit of normal (ULN)          │ institutional upper limit of normal (ULN)          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum creatinine less than or equal to 2.0 mg/dL   │ Serum creatinine less than or equal to 2.0 mg/dL   │     100 │
│ (Note: Patients with a serum creatinine greater    │ (Note: Patients with a serum creatinine greater    │         │
│ than or equal to 1.4 and less than or equal to 2.0 │ than or equal to 1.4 and less than or equal to 2.0 │         │
│ mg/dL must demonstrate a 24-hour urinary           │ mg/dL must demonstrate a 24-hour urinary           │         │
│ creatinine clearance greater than or equal to 50   │ creatinine clearance greater than or equal to 50   │         │
│ mL/min)                                            │ mL/min)                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Females of childbearing potential: negative serum  │ Females of childbearing potential: negative serum  │     100 │
│ or urine pregnancy test                            │ or urine pregnancy test                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient must give written informed consent before  │ Patient must give written informed consent before  │     100 │
│ participating in any study-specific procedure,     │ participating in any study-specific procedure,     │         │
│ randomization, or receiving investigational        │ randomization, or receiving investigational        │         │
│ product                                            │ product                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with reproductive capability must agree   │ Patients with reproductive capability must agree   │     100 │
│ to practice adequate contraception methods         │ to practice adequate contraception methods         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Metastatic disease (M1)/stage 4 NSCLC              │ Metastatic disease (M1)/stage 4 NSCLC              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pleural or pericardial effusion greater than 100   │ Pleural or pericardial effusion greater than 100   │     100 │
│ ml in volume as documented by appropriate imaging  │ ml in volume as documented by appropriate imaging  │         │
│ (positron emission tomography \[PET\], computed    │ (positron emission tomography [PET], computed      │         │
│ tomography \[CT\] scan or ultrasound). If an       │ tomography [CT] scan or ultrasound). If an         │         │
│ effusion greater than 100 ml is documented by      │ effusion greater than 100 ml is documented by      │         │
│ cytology to be free from malignancy and the        │ cytology to be free from malignancy and the        │         │
│ investigator feels the patient is capable of       │ investigator feels the patient is capable of       │         │
│ receiving chemo/radiotherapy for their primary     │ receiving chemo/radiotherapy for their primary     │         │
│ disease/ NSCLC, the investigator should discuss    │ disease/ NSCLC, the investigator should discuss    │         │
│ the patient with the study physician at Amgen.     │ the patient with the study physician at Amgen.     │         │
│ Effusions smaller than 100 ml would be acceptable, │ Effusions smaller than 100 ml would be acceptable, │         │
│ unless the investigator suspects that the effusion │ unless the investigator suspects that the effusion │         │
│ is malignant, in which case the effusions should   │ is malignant, in which case the effusions should   │         │
│ be evaluated by cytology. Sponsor approval must be │ be evaluated by cytology. Sponsor approval must be │         │
│ obtained before patient is randomized              │ obtained before patient is randomized              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Plan to remove the tumor surgically before         │ Plan to remove the tumor surgically before         │     100 │
│ completing the protocol chemo/radiotherapy course  │ completing the protocol chemo/radiotherapy course  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Shielding of any part of the esophagus during      │ Shielding of any part of the esophagus during      │     100 │
│ radiotherapy (including posterior spinal cord      │ radiotherapy (including posterior spinal cord      │         │
│ shielding)                                         │ shielding)                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior chemotherapy, radiotherapy, or surgery for   │ Prior chemotherapy, radiotherapy, or surgery for   │     100 │
│ NSCLC                                              │ NSCLC                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior invasive malignancy during the past 3 years  │ Prior invasive malignancy during the past 3 years  │     100 │
│ other than non-melanomatous skin cancer. Note:     │ other than non-melanomatous skin cancer. Note:     │         │
│ Patients with prior surgically-cured malignancies  │ Patients with prior surgically-cured malignancies  │         │
│ \[eg, stage I breast cancer or prostate cancer,    │ [eg, stage I breast cancer or prostate cancer, in- │         │
│ in-situ carcinoma of the cervix, etc\] are not     │ situ carcinoma of the cervix, etc] are not         │         │
│ excluded; however, sponsor approval must be        │ excluded; however, sponsor approval must be        │         │
│ obtained before patient is randomized              │ obtained before patient is randomized              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of pancreatitis                            │ History of pancreatitis                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Four weeks or less since completion of treatment   │ Four weeks or less since completion of treatment   │     100 │
│ using an investigational product/device in another │ using an investigational product/device in another │         │
│ clinical study or presence of any unresolved       │ clinical study or presence of any unresolved       │         │
│ toxicity from previous treatment                   │ toxicity from previous treatment                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous treatment on this study or with a         │ Previous treatment on this study or with a         │     100 │
│ fibroblast growth factor                           │ fibroblast growth factor                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known to be sero-positive for human                │ Known to be sero-positive for human                │     100 │
│ immunodeficiency virus (HIV), hepatitis C virus    │ immunodeficiency virus (HIV), hepatitis C virus    │         │
│ (HCV), or hepatitis B virus (HBV)                  │ (HCV), or hepatitis B virus (HBV)                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or breastfeeding women                    │ Pregnant or breastfeeding women                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known sensitivity to E. coli derived products      │ Known sensitivity to E. coli derived products      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Compromised ability of the patient to give written │ Compromised ability of the patient to give written │     100 │
│ informed consent and/or to comply with study       │ informed consent and/or to comply with study       │         │
│ procedures                                         │ procedures                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Refusal to sign an informed consent form to        │ Refusal to sign an informed consent form to        │     100 │
│ participate in this study, and sign the hospital   │ participate in this study, and sign the hospital   │         │
│ information release form, if applicable            │ information release form, if applicable            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unwilling or unable to complete the patient        │ Unwilling or unable to complete the patient        │     100 │
│ reported outcome (PRO) questionnaires              │ reported outcome (PRO) questionnaires              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Psychological, social, familial, or geographical   │ Psychological, social, familial, or geographical   │     100 │
│ reasons that would prevent regular follow-up       │ reasons that would prevent regular follow-up       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Platelet count greater than or equal to 100 x      │ Platelet count greater than or equal to 100 x      │      99 │
│ 10\^9/L                                            │ 10^9/L                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence or history of dysphagia or conditions     │ Presence or history of dysphagia or conditions     │      99 │
│ predisposing to dysphagia (eg, uncontrolled        │ predisposing to dysphagia (eg, uncontrolled        │         │
│ gastroesophageal reflux disease \[GERD\],          │ gastroesophageal reflux disease [GERD], dyspepsia, │         │
│ dyspepsia, etc)                                    │ etc)                                               │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤══════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria            │   Score │
╞═══════════════════════════════════╪══════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ 18 years of age or older │      42 │
╘═══════════════════════════════════╧══════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 98.23529411764706
OverAll Ratio: 98.61764705882354
